NasdaqCM - Delayed Quote USD

Aptevo Therapeutics Inc. (APVO)

0.7061 +0.0261 (+3.84%)
At close: April 26 at 4:00 PM EDT
0.7000 -0.01 (-0.86%)
After hours: April 26 at 7:48 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Marvin L. White President, CEO & Director 841.39k -- 1962
Mr. Jeffrey G. Lamothe CA Executive VP & COO 722.51k -- 1966
Ms. SoYoung Kwon J.D., LL.M. Senior VP, General Counsel, Business Development & Corporate Affairs 639.37k -- 1969
Ms. Daphne L. Taylor Senior VP & CFO -- -- 1966
Dr. Dirk Huebner M.D. Chief Medical Officer -- -- 1964

Aptevo Therapeutics Inc.

2401 4th Avenue
Suite 1050
Seattle, WA 98121
United States
206 838 0500 https://www.aptevotherapeutics.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
40

Description

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Corporate Governance

Aptevo Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 09, 2024 - May 13, 2024
Aptevo Therapeutics Inc. Earnings Call

Related Tickers

ALLR Allarity Therapeutics, Inc.
1.4600
+2.10%
 
EFTR eFFECTOR Therapeutics, Inc.
1.8900
+4.42%
 
GLTO Galecto, Inc.
0.7048
+5.62%
 
ATXI Avenue Therapeutics, Inc.
6.20
-29.35%
 
RNAZ TransCode Therapeutics, Inc.
0.5499
+5.30%
 
KA Kineta, Inc.
0.6100
-2.37%
 
FNCH Finch Therapeutics Group, Inc.
2.3200
+3.11%
 
KRON Kronos Bio, Inc.
1.0000
+2.04%
 
CYCC Cyclacel Pharmaceuticals, Inc.
1.5100
-5.63%
 
BPTS Biophytis S.A.
8.22
0.00%